Drug Profile
Avexitide - Eiger BioPharmaceuticals
Alternative Names: Avexitide acetate; Exendin (9-39)amide; Exendin 9; Exendin 9-39 acetate; Exendin-(9-39); Exendin-9,39Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator Stanford University
- Developer Cambridge University Hospitals; Eiger BioPharmaceuticals, Inc.; Stanford University
- Class Antihypoglycaemics; Peptide fragments
- Mechanism of Action Glucagon-like peptide-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Congenital hyperinsulinism
- Phase II Hypoglycaemia
Most Recent Events
- 31 Dec 2023 Eiger Biopharmaceuticals has patent protection for avexitide in Europe, Australia, Chile (Eiger BioPharmaceuticals_10-K_SEC-filing_Dec-2023 (3851850)
- 07 Sep 2023 9397658: No updates (Annual Global Investment Conference info-designation info already covered)
- 04 Aug 2022 Phase-III clinical trials in Congenital-hyperinsulinism